Natixis Bridge Bio Pharma, Inc. Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Natixis holds 18,500 shares of BBIO stock, worth $537,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,500

Holding current value

$537,980

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$23.91 - $31.3 $442,335 - $579,050	18,500 New	18,500 $471,000
Q3 2023 Nov 14, 2023	BUY	$16.89 - $35.01 $435,762 - $903,258	25,800 Added 430.0%	31,800 $838,000
Q2 2023 Aug 11, 2023	SELL	$13.29 - $18.01 $119,609 - $162,090	-9,000 Reduced 60.0%	6,000 $103,000
Q1 2023 May 12, 2023	BUY	$7.17 - $18.55 $107,550 - $278,250	15,000 New	15,000 $248,000
Q4 2021 Feb 14, 2022	SELL	$11.38 - $53.41 $334,287 - $1.57 Million	-29,375 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$46.87 - $64.24 $1.11 Million - $1.52 Million	23,725 Added 419.91%	29,375 $1.38 Million
Q2 2021 Aug 13, 2021	BUY	$46.47 - $63.93 $58,087 - $79,912	1,250 Added 28.41%	5,650 $344,000
Q1 2021 May 14, 2021	BUY	$55.47 - $72.35 $244,068 - $318,340	4,400 New	4,400 $271,000

Others Institutions Holding BBIO

# of Institutions

290

Shares Held

170M

Call Options Held

10.4M

Put Options Held

2.37M

Kohlberg Kravis Roberts & Co. L.P. New York, NY

25.3M
Shares

$735 Million
35.94% of portfolio
Viking Global Investors LP

25.1M
Shares

$731 Million
2.47% of portfolio
Vanguard Group Inc Valley Forge, PA

14.2M
Shares

$413 Million
0.01% of portfolio
Black Rock Inc. New York, NY

12.4M
Shares

$362 Million
0.01% of portfolio
Aisling Capital Management LP New York, NY

6.07M
Shares

$176 Million
63.58% of portfolio

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $4.31B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account